Drugs and Pharmaceuticals News

SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. Clinical data from on-going studies in Los Angeles, California, indicating dose-dependent tumor control rates and survival benefits with no major toxicity in Rexin-G-treated patients prompted the extension of these clinical trials to the East Coast.

Rexin-G has gained orphan drug status from the U.S. FDA for three clinical indications: pancreatic cancer, osteosarcoma and soft tissue sarcoma.

The New York clinical trials will be conducted at the Bruckner Oncology Center in Manhattan, New York with Howard W. Bruckner, M.D. as the Principal Investigator. Dr. Bruckner is a board certified medical oncologist who trained at Yale University School of Medicine and performed research at the NIH with specialists and collaborative groups.

Dr. Bruckner is internationally renowned for his work in pancreatic, breast, gastrointestinal, colon, and ovarian cancers and was the first medical oncologist to treat patients with Rexin-G for advanced pancreatic cancer in the United States (Int'l J Oncol 2006). He has served as an Expert Consultant and Safety Monitor for the National Surgical Adjuvant Project for Breast and Bowel Cancers Project (NSABP) sponsored by the National Cancer Institute.

For further information concerning these clinical trials in New York, please go to www.clinicaltrials.gov and search Epeius-sponsored protocols C07-104 and C07-105.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius' pipeline of proprietary compounds currently available for outlicensing and clinical development, please visit us at www.epeiusbiotech.com


NEWS SOURCE: Epeius Biotechnologies

Send2Press® is the originating wire service for this story.

PRESS RELEASE PERMALINK: http://www.send2press.com/newswire/2008-10-1029-003.shtml

For more information about this news release, contact Epeius Biotechnologies directly through their Web site found in the above press release, and NOT Send2Press.

Copyright © 2008 by Send2Press® Newswire, part of the Neotrope® News Network (California, USA). All rights reserved. License/Terms of Use: Attribution Required ("Send2Press® is the originating wire service").